肝硬化成为他汀类药物的新适应证
本文综述了他汀类药物在晚期慢性肝病中的有利作用证据,包括降低门静脉压力、改善肝窦内皮与肝微血管功能障碍、减少纤维化、抗缺血再灌注损伤等。基于这些机制与临床研究证据,他汀从慢性肝病患者的风险因素转变为潜在的有益药物。
要点
- 他汀可降低门静脉压力并改善肝窦内皮功能障碍。
- 他汀具有抗纤维化、抗缺血再灌注损伤及延长移植物保存的潜力。
- 他汀可能延缓任何病因肝硬化的进展并预防肝细胞癌。
核心结论
- 他汀在晚期慢性肝病患者中表现出多种有利效应,从理论机制到临床研究证据支持其成为慢性肝病的潜在治疗药物。
研究设计与样本
- 本文为综述,汇总他汀在慢性肝病中潜在应用的机制背景与临床研究客观证据。
主要发现
- 他汀可降低门静脉压力、改善肝窦内皮和肝微血管功能障碍、减少纤维化。
- 他汀可保护缺血再灌注损伤、安全延长离体肝移植物保存、降低对内毒素介导肝损伤的敏感性。
- 他汀可预防慢加急性肝衰竭、预防低血容量休克后肝损伤、预防或延缓任何病因肝硬化的进展。
- 他汀在慢性硬化性胆管炎进展和预防肝细胞癌方面也显示潜在有益作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the recent years, there have been an increasing number of reports on favourable effects of statins in patients with advanced chronic liver disease. These include reduction in portal pressure, improved liver sinusoidal endothelial and hepatic microvascular dysfunction, decreased fibrogenesis, protection against ischaemia/reperfusion injury, safe prolongation of ex vivo liver graft preservation, reduced sensitivity to endotoxin-mediated liver damage, protection from acute-on-chronic liver failure, prevention of liver injury following hypovolaemic shock and preventing/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the progression of other liver diseases, such as chronic sclerosing cholangitis and in preventing hepatocellular carcinoma. Because of these many theoretically favourable effects, statins have evolved from being considered a risk to kind of wonder drugs for patients with chronic liver diseases. The present article reviews the current knowledge on the potential applications of statins in chronic liver diseases, from its mechanistic background to objective evidence from clinical studies.
引用
- Bosch J, Gracia-Sancho J, Abraldes JG, et al. Cirrhosis as new indication for statins. Gut. 2020. PMID: 32139553. doi:10.1136/gutjnl-2019-318237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。